201 related articles for article (PubMed ID: 37217634)
1. Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Morales-Barrera R; Villacampa G; Vidal N; Figols M; Giner J; Bonfill T; Suárez C; Díaz N; Mateo J; González M; Domenech M; Puente J; Carles J
Clin Transl Oncol; 2023 Dec; 25(12):3556-3564. PubMed ID: 37217634
[TBL] [Abstract][Full Text] [Related]
2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias.
Otsuka H; Kita Y; Ito K; Sano T; Inokuchi J; Tomida R; Takahashi A; Matsumoto K; Kurahashi R; Ozaki Y; Uegaki M; Maruyama S; Mukai S; Tsutsumi M; Kawahara T; Segawa T; Kitamura H; Morita S; Kobayashi T
Cancer Sci; 2022 Nov; 113(11):3912-3921. PubMed ID: 35997546
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
5. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
6. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
7. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
Kfoury M; Najean M; Lappara A; Voisin AL; Champiat S; Michot JM; Laghouati S; Robert C; Besse B; Soria JC; Lambotte O; Massard C; Marabelle A; Texier M
Cancer Treat Rev; 2022 Nov; 110():102452. PubMed ID: 35998515
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S; Joshi SS; Narayan VM; Kissick H; Ogan K; Master VA; Carthon BC; Kucuk O; Bilen MA
Oncologist; 2023 Dec; 28(12):1072-1078. PubMed ID: 37285524
[TBL] [Abstract][Full Text] [Related]
10. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers.
Schulz GB; Rodler S; Szabados B; Graser A; Buchner A; Stief C; Casuscelli J
J Geriatr Oncol; 2020 Sep; 11(7):1061-1066. PubMed ID: 32565147
[TBL] [Abstract][Full Text] [Related]
12. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Daban A; Gonnin C; Phan L; Saldmann A; Granier C; Lillo-Lelouet A; Le Beller C; Pouchot J; Weiss L; Tartour E; Fabre E; Medioni J; Oudard S; Vano YA; Dragon-Durey MA; Simonaggio A
Oncoimmunology; 2023; 12(1):2204754. PubMed ID: 37187974
[TBL] [Abstract][Full Text] [Related]
13. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
14. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review.
Kijima T; Fukushima H; Kusuhara S; Tanaka H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Sakai Y; Saito K; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Clin Genitourin Cancer; 2021 Jun; 19(3):208-216.e1. PubMed ID: 32800718
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.
Wang W; Lin G; Hao Y; Guan Y; Zhang Y; Xu C; Wang Q; Wang D; Jiang Z; Cai J; Lou G; Song Z; Zhang Y
Eur J Cancer; 2022 Oct; 174():21-30. PubMed ID: 35970032
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.
Huang G; Xiong H; Li S; Zhu Y; Liu H
J Cancer Res Clin Oncol; 2024 Jan; 150(1):5. PubMed ID: 38170235
[TBL] [Abstract][Full Text] [Related]
17. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
18. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
20. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
